寻求合作
[供] 意大利机构提供生产用作放射性药物前体的高纯放射性核素
合作类型:技术     行业类别: 生物科学与健康     国家:意大利
发布时间:2018年03月26日     过期时间:2020年12月20日     点击数:5

意大利一个研究小组开发了一种新技术,用于生产高质量的放射性核素作为放射性药物前体。 由低能商用回旋加速器产生的等压光束被用于生产无载体放射性核素。寻求放射性药物行业和医院开发新的放射性药物或通过技术或许可协议有效改善传统放射性核素的生产。

An Italian research group has developed a new technology for the production of very high quality radionuclides as radiopharmaceutical precursors. The isobaric beams generated by a low-energy commercially available cyclotron are applied for the production of carrier-free radionuclides. Radiopharmaceutical industries and hospitals are sought for developing new radiopharmaceuticals or effectively improving the production of the conventional radionuclides through technical or licensing agreements.

Description     

Radionuclides for radiopharmaceutical preparation are currently produced in cyclotrons, generators or nuclear reactors. However, none of these modalities is free from serious shortcomings, such as: high costs of targets, co-production of undesired radionuclides contaminating the final product, laborious and expensive separation methods and formation of large quantities of radioactive wastes.

The ISOL technique (IsoTope Separation On-Line) is nowadays widely recognized as a major pathway for the production of high intensity and high quality radioactive ion beams for nuclear physics studies. The fact that it allows to produce exotic nuclei with: i) high efficiency, ii) high rate and iii) great selectivity makes it ideally suitable for production of high-specific activity beta emitters, as those required for the preparation of modern theranostic molecular radiopharmaceuticals (MRs).

According to the newly proposed method with the aforementioned unique features it will be possible to produce radionuclides with specific activities superior to those provided in standard facilities and free from radionuclide and chemical impurities.

Through a primary accelerator (for istance a cyclotron), a low energy proton beam irradiates a target to generate neutral radioactive atoms which are ionized and extracted by acceleration. After being focused, the beam undergoes mass separation to generate an isobaric beam of radionuclides. The beam is subjected to a second focusing and it is sent for a predetermined time on a deposition target. The irradiated deposition target is eventually chemically treated to yield “carrier-free” radionuclides. The Italian research group is looking for radiopharmaceutical industries and hospitals for testing and  developing new radiopharmaceuticals or effectively improving the production of the conventional radionuclides through technical or licensing agreements.

 

Type and Role of Partner Sought    

Private companies or research centers on radiopharmaceutical science or hospitals for testing and  developing new radiopharmaceuticals or effectively improving the production of the conventional radionuclides through technical or licensing agreements.

【供】180053 TOIT20171106002
回复列表
1 / 共0页


发表回复:
请在下面登录后,才能发表回复
会员帐号: 密码: